AABB’s Regulatory Affairs staff and Transfusion-Transmitted Diseases (TTD) Committee work closely with the FDA and CDC to monitor emerging malaria risks and to provide information and current recommendations from CDC. The TTD Committee as well as the Donor History Task Force include representatives from FDA and CDC.
Follow the current FDA Guidance Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria
FDA’s December 2022 Guidance, defines exposure timeframes for residence in, or travel to, a malaria-endemic country or malaria endemic area. “The recommendations in this guidance for screening blood donors for malaria risk and for implementing pathogen reduction of indicated blood components are based on the current epidemiological data on malaria and the risk of transfusion-transmitted malaria, and on the availability of FDA-approved pathogen reduction devices.”
Review AABB’s Emerging Infectious Disease Fact Sheet, Plasmodium Species
Note: The donor deferral recommendations in this 2009 Fact Sheet are outdated. Refer to the DHQ webpage and DHQ v4.0 for current recommendations. This Fact Sheet is under revision.
This list is updated periodically. Refer to the CDC links listed above for current recommendations.
06/27/23
Malaria Cases Reported in Florida and Texas
CDC recently issued a Health Alert Network Health Advisory in response to
several confirmed cases of locally acquired malaria in Florida and Texas.
04/19/23
CDC Expands Malaria Chemoprophylaxis Recommendation in Costa Rica
The Centers for Disease Control
and Prevention expanded its malaria chemoprophylaxis recommendation for travelers to Costa Rica in response to an outbreak of Plasmodium falciparum malaria.